Trial Overview
NCT ID: NCT04161066 Phase: PHASE1 Enrollment Target: 10 Status: Recruiting
Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation.
Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy.
Secondary Aim: To evaluate the effect of concurrent buprenorphine-naloxone use on the effects of psilocybin therapy.
Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.
Why This Matters
[Draft — editorial context needed]
Source
Event Website
ClinicalTrials.gov
